Two extraordinary scientists, Lingbing Zhang and Suzanne Kennedy, share their revolutionary approach to treating cancer cachexia, a deadly wasting syndrome that affects 80% of stage four cancer patients and causes 30% of cancer deaths despite receiving almost no attention in mainstream treatment.

• Personal journeys led both scientists to study cachexia - Kennedy after losing a childhood friend to leukemia and Zhang through his fascination with immunology
• Cachexia is not simply weight loss but an immune disorder causing the body to destroy itself
• Unlike popular belief, increased caloric intake cannot reverse cachexia
• 30% of cancer patients die from cachexia rather than their primary cancer
• Nearly all pancreatic cancer patients have had cachexia for a year when first diagnosed
• The scientists left prestigious positions to found Akexis, developing the first drug targeting the immune dysfunction driving cachexia
• Their treatment could revolutionize cancer care by allowing anti-tumor treatments to work more effectively
• The drug has completed preclinical work and proof of concept trials with promising results
• Their team includes renowned cancer researchers from Cedars-Sinai and Rush University

To learn more about their groundbreaking work or support their mission, visit akexis.com

Ready to optimize culture and transform engagement?
Visit https://commix.io to learn more.

Commix.io
AI Culture Optimization software to help leaders get organizational health insights in real-time.

Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.

Read to optimize culture and Transform employee engagement? Visit Commix.io